INFU vs ACLX vs LEGN vs BRT vs FATE

For growth investors, Legend Biotech Corporation (LEGN) is the stronger pick with 64.

5% revenue growth year-over-year, versus -79. 4% for Arcellx, Inc. (ACLX). InfuSystem Holdings, Inc. (INFU) offers the better valuation at 27. 1x trailing P/E (19. 8x forward), making it the more compelling value choice. Analysts rate InfuSystem Holdings, Inc. (INFU) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, InfuSystem Holdings, Inc.

is actually cheaper at 19. 8x.

Over the past 5 years, Arcellx, Inc.

(ACLX) delivered a total return of +584. 9%, compared to -96. 8% for Fate Therapeutics, Inc. (FATE). Over 10 years, the gap is even starker: ACLX returned +584. 9% versus LEGN's -24. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Arcellx, Inc.

(ACLX) is the lower-risk stock at -0. 49β versus Fate Therapeutics, Inc. 's 1. 99β — meaning FATE is approximately -506% more volatile than ACLX relative to the S&P 500. On balance sheet safety, InfuSystem Holdings, Inc. (INFU) carries a lower debt/equity ratio of 6% versus 3% for BRT Apartments Corp. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Legend Biotech Corporation (LEGN) is pulling ahead at 64.

5% versus -79. 4% for Arcellx, Inc. (ACLX). On earnings-per-share growth, the picture is similar: InfuSystem Holdings, Inc. grew EPS 181. 8% year-over-year, compared to -103. 5% for Arcellx, Inc.. Over a 3-year CAGR, LEGN leads at 106. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

InfuSystem Holdings, Inc.

(INFU) is the more profitable company, earning 4. 6% net margin versus -20. 5% for Fate Therapeutics, Inc. — meaning it keeps 4. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BRT leads at 11. 4% versus -22. 2% for FATE. At the gross margin level — before operating expenses — ACLX leads at 70. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, InfuSystem Holdings, Inc.

(INFU) trades at 19. 8x forward P/E versus 116. 2x for Legend Biotech Corporation — 96. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for FATE: 1552. 7% to $39. 50.

In this comparison, BRT (7.

2% yield) pays a dividend. INFU, ACLX, LEGN, FATE do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Arcellx, Inc.

(ACLX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 49), +584. 9% 10Y return). Fate Therapeutics, Inc. (FATE) carries a higher beta of 1. 99 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ACLX: +584. 9%, FATE: +38. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (INFU (Healthcare) and ACLX (Healthcare) and LEGN (Healthcare) and BRT (Real Estate) and FATE (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: INFU is a small-cap quality compounder stock; ACLX is a small-cap quality compounder stock; LEGN is a small-cap high-growth stock; BRT is a small-cap income-oriented stock; FATE is a small-cap quality compounder stock. BRT pays a dividend while INFU, ACLX, LEGN, FATE do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.